1. CzajaAJ, MannsMP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology2010;139:58. CrossRef

2. WaldenstromJ. [Liver, blood proteins and food proteins]. Dtsch Z Verdau Stoffwechselkr1952;12(Spec No):113.

3. CowlingDC, MackayIR, TaftLI. Lupoid hepatitis. Lancet1956;271:1323.

4. JohnsonPJ, McFarlaneIG. Meeting report: International Autoimmune Hepatitis Group. Hepatology1993;18:998. CrossRef

5. MannsMP, CzajaAJ, GorhamJD, et al.Diagnosis and management of autoimmune hepatitis. Hepatology2010;51:2193. CrossRef

6. LiberalR, GrantCR, Mieli‐VerganiG, et al.Autoimmune hepatitis: a comprehensive review. J Autoimmun2013;41:126. CrossRef

7. BelandK, LapierreP, AlvarezF. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J Gastroenterol2009;15:1025. CrossRef

8. Al‐ChalabiT, BoccatoS, PortmannBC, et al.Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol2006;45:575. CrossRef

9. VerganiGM, VerganiD, JenkinsPJ, et al.Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg‐negative chronic active hepatitis. Clin Exp Immunol1979;38:16.

10. VerganiD, Mieli‐VerganiG, MondelliM, et al.Immunoglobulin on the surface of isolated hepatocytes is associated with antibody‐dependent cell‐mediated cytotoxicity and liver damage. Liver1987;7:307. CrossRef

11. WachterB, KyriatsoulisA, LohseAW, et al.Characterization of liver cytokeratin as a major target antigen of anti‐SLA antibodies. J Hepatol1990;11:232. CrossRef

12. MuratoriL, ParolaM, RipaltiA, et al.Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut2000;46:553. CrossRef

13. LapierreP, HajouiO, HombergJC, et al.Formiminotransferase cyclodeaminase is an organ‐specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology1999;116:643. CrossRef

14. Hardtke‐WolenskiM, FischerK, NoyanF, et al.Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology2013;58:718. CrossRef

15. McFarlaneBM, McSorleyCG, VerganiD, et al.Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol1986;3:196. CrossRef

16. MannsM, GerkenG, KyriatsoulisA, et al.Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet1987;1:292. CrossRef

17. StechemesserE, KleinR, BergPA. Characterization and clinical relevance of liver‐pancreas antibodies in autoimmune hepatitis. Hepatology1993;18:1. CrossRef

18. WiesI, BrunnerS, HenningerJ, et al.Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet2000;355:1510. CrossRef

19. CostaM, Rodriguez‐SanchezJL, CzajaAJ, et al.Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype‐1 autoimmune hepatitis. Clin Exp Immunol2000;121:364. CrossRef

20. BogdanosDP, Mieli‐VerganiG, VerganiD. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis2009;29:241. CrossRef

21. MaruokaR, AokiN, KidoM, et al.Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology2013;145:209. CrossRef

22. SenaldiG, PortmannB, MowatAP, et al.Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child1992;67:1447. CrossRef

23. WenL, PeakmanM, Lobo‐YeoA, et al.T‐cell‐directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet1990;336:1527. CrossRef

24. WenL, MaY, BogdanosDP, et al.Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med2001;1:379. CrossRef

25. MixH, Weiler‐NormannC, ThimmeR, et al.Identification of CD4 T‐cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology2008;135:2107. CrossRef

26. LonghiMS, HussainMJ, BogdanosDP, et al.Cytochrome P450IID6‐specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology2007;46:472. CrossRef

27. MaY, BogdanosDP, HussainMJ, et al.Polyclonal T‐cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology2006;130:868. CrossRef

28. FerriS, LonghiMS, De MoloC, et al.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology2010;52:999. CrossRef

29. LonghiMS, MaY, BogdanosDP, et al.Impairment of CD4(+)CD25(+) regulatory T‐cells in autoimmune liver disease. J Hepatol2004;41:31. CrossRef

30. LonghiMS, HussainMJ, MitryRR, et al.Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol2006;176:4484. CrossRef

31. LonghiMS, MaY, Mieli‐VerganiG, et al.Adaptive immunity in autoimmune hepatitis. Dig Dis2010;28:63. CrossRef

32. LonghiMS, MaY, GrantCR, et al.T‐regs in autoimmune hepatitis‐systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile. J Autoimmun2013;41:146. CrossRef

33. PeiselerM, SebodeM, FrankeB, et al.FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol2012;57:125. CrossRef

34. OliveiraLC, PortaG, MarinML, et al.Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev2011;10:189. CrossRef

35. AlvarezF, BergPA, BianchiFB, et al.International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol1999;31:929. CrossRef

36. TangJ, ZhouC, ZhangZJ, et al.Association of polymorphisms in non‐classic MHC genes with susceptibility to autoimmune hepatitis. Hepatobiliary Pancreat Dis Int2012;11:125. CrossRef

37. VogelA, StrassburgCP, MannsMP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology2002;35:126. CrossRef

38. MigitaK, NakamuraM, AbiruS, et al.Association of STAT4 polymorphisms with susceptibility to type‐1 autoimmune hepatitis in the Japanese population. PLoS ONE2013;8:e71382. CrossRef

39. LankischTO, JaeckelE, StrassburgCP. The autoimmune polyendocrinopathy‐candidiasis‐ectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin Liver Dis2009;29:307. CrossRef

40. VogelA, LiermannH, HarmsA, et al.Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology2001;33:1047. CrossRef

41. EhserJ, HoldenerM, ChristenS, et al.Molecular mimicry rather than identity breaks T‐cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun2013;42:39. CrossRef

42. GregorioGV, ChoudhuriK, MaY, et al.Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol1999;162:1802.

43. GregorioGV, ChoudhuriK, MaY, et al.Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol2003;133:404. CrossRef

44. KerkarN, ChoudhuriK, MaY, et al.Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross‐reactivity in liver kidney microsomal autoantibody type 1‐positive liver disease. J Immunol2003;170:1481. CrossRef

45. Mieli‐VerganiG, VerganiD. Autoimmune hepatitis in children: what is different from adult AIH?Semin Liver Dis2009;29:297. CrossRef

46. KrawittEL. Autoimmune hepatitis. N Engl J Med2006;354:54. CrossRef

47. TeufelA, WeinmannA, KahalyGJ, et al.Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol2010;44:208. CrossRef

48. GelpiC, SontheimerEJ, Rodriguez‐SanchezJL. Autoantibodies against a serine tRNA‐protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A1992;89:9739. CrossRef

49. StrassburgCP, MannsMP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis2002;22:339. CrossRef

50. BobergKM, ChapmanRW, HirschfieldGM, et al.Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol2011;54:374. CrossRef

51. CzajaAJ, MannsMP, HomburgerHA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology1992;103:1290.

52. DienesHP, DrebberU. Pathology of immune‐mediated liver injury. Dig Dis2010;28:57. CrossRef

53. SuzukiA, BruntEM, KleinerDE, et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug‐induced liver injury. Hepatology2011;54:931. CrossRef

54. BenselerV, WarrenA, VoM, et al.Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A2011;108:16735. CrossRef

55. RobertsEA, SchilskyML. Diagnosis and treatment of Wilson disease: an update. Hepatology2008;47:2089. CrossRef

56. GregorioGV, PortmannB, KaraniJ, et al.Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16‐year prospective study. Hepatology2001;33:544. CrossRef

57. ChalasaniN, YounossiZ, LavineJE, et al.The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology2012;142:1592. CrossRef

58. HennesEM, ZeniyaM, CzajaAJ, et al.Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology2008;48:169. CrossRef

59. CzajaAJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology2008;48:1540. CrossRef

60. YeomanAD, WestbrookRH, Al‐ChalabiT, et al.Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology2009;50:538. CrossRef

61. EbbesonRL, SchreiberRA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?Clin Gastroenterol Hepatol2004;2:935. CrossRef

62. HiejimaE, KomatsuH, SogoT, et al.Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children. J Pediatr Gastroenterol Nutr2011;52:470. CrossRef

63. MuratoriP, GranitoA, PappasG, et al.Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology2009;49:1782, author reply 3. CrossRef

64. CookGC, MulliganR, SherlockS. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med1971;40:159. CrossRef

65. Murray‐LyonIM, SternRB, WilliamsR. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet1973;1:735.

66. SummerskillWH, KormanMG, AmmonHV, et al.Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut1975;16:876. CrossRef

67. KirkAP, JainS, PocockS, et al.Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut1980;21:78. CrossRef

68. RobertsSK, TherneauTM, CzajaAJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology1996;110:848. CrossRef

69. CzajaAJ, CarpenterHA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol2004;40:646. CrossRef

70. CzajaAJ, CarpenterHA, SantrachPJ, et al.Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol1993;18:342. CrossRef

71. StellonAJ, KeatingJJ, JohnsonPJ, et al.Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology1988;8:781. CrossRef

72. JohnsonPJ, McFarlaneIG, WilliamsR. Azathioprine for long‐term maintenance of remission in autoimmune hepatitis. N Engl J Med1995;333:958. CrossRef

73. MannsMP, WoynarowskiM, KreiselW, et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology2010;139:1198. CrossRef

74. HempflingW, GrunhageF, DilgerK, et al.Pharmacokinetics and pharmacodynamic action of budesonide in early‐ and late‐stage primary biliary cirrhosis. Hepatology2003;38:196. CrossRef

75. MederackeI, HelfritzF, PulsF, et al.Budd‐Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol2012;11:143.

76. GleesonD, HeneghanMA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut2011;60:1611. CrossRef

77. SchrammC, Weiler‐NormannC, WiegardC, et al.Treatment response in patients with autoimmune hepatitis. Hepatology2010;52:2247. CrossRef

78. WoynarowskiM, NemethA, BaruchY, et al.Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr2013;163:1347. CrossRef

79. VermaS, GunuwanB, MendlerM, et al.Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol2004;99:1510. CrossRef

80. Montano‐LozaAJ, CarpenterHA, CzajaAJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol2007;102:1005. CrossRef

81. MuratoriL, MuratoriP, LanzoniG, et al.Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology2010;52:1857, author reply 1857. CrossRef

82. MuratoriP, GranitoA, QuarnetiC, et al.Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol2009;50:1210. CrossRef

83. CzajaAJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol2009;51:161. CrossRef

84. van GervenNM, VerwerBJ, WitteBI, et al.Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol2013;58:141. CrossRef

85. MaY, OkamotoM, ThomasMG, et al.Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology2002;35:658. CrossRef

86. HoeroldtB, McFarlaneE, DubeA, et al.Long‐term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology2011;140:1980. CrossRef

87. YoshizawaK, MatsumotoA, IchijoT, et al.Long‐term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology2012;56:668. CrossRef

88. WestbrookRH, YeomanAD, KrieseS, et al.Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun2012;38:J239. CrossRef

89. FranulovicOZ, RajacicN, LesarT, et al.Cyclosporine induced biochemical remission in childhood autoimmune hepatitis. Coll Antropol2012;36:973.

90. CzajaAJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci2012;57:1996. CrossRef

91. ZachouK, GatselisN, PapadamouG, et al.Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment‐naive patients. J Hepatol2011;55:636. CrossRef

92. OoYH, HubscherSG, AdamsDH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int2010;4:475. CrossRef

93. Weiler‐NormannC, SchrammC, QuaasA, et al.Infliximab as a rescue treatment in difficult‐to‐treat autoimmune hepatitis. J Hepatol2013;58:529. CrossRef

94. MannsMP, MixH. Emerging entities of immune‐mediated allograft dysfunction after liver transplantation?Am J Transplant2013;13:2792. CrossRef

95. NguJH, GearryRB, FramptonCM, et al.Mortality and the risk of malignancy in autoimmune liver diseases: a population‐based study in Canterbury, New Zealand. Hepatology2012;55:522. CrossRef

96. NguJH, GearryRB, FramptonCM, et al.Predictors of poor outcome in patients with autoimmune hepatitis: a population‐based study. Hepatology2013;57:2399. CrossRef

97. WangKK, CzajaAJ, BeaverSJ, et al.Extrahepatic malignancy following long‐term immunosuppressive therapy of severe hepatitis B surface antigen‐negative chronic active hepatitis. Hepatology1989;10:39. CrossRef